Abstract
Beryllium induces non-caseating granulomatous inflammation in humans exposed to the metal dust or fumes in both occupational and non-occupational settings. The resulting condition, chronic beryllium disease (CBD), affects principally the lungs, lymphatics, and skin and continues to plague modern industry. Beryllium exerts several important immunotoxic effects, including induction of a beryllium-antigen specific adaptive immune response and the triggering of inflammatory and innate immune responses. Genetic susceptibility plays a role in CBD adaptive immune responses, mainly mediated through single nucleotide polymorphisms in HLA-DP and, to a lesser extent, HLA-DR. The adaptive response is characterized by influx and proliferation of CD4+ central and effector memory T cells expressing Th1 cytokines. Insights into the immunopathogenesis of CBD have implications for the understanding of other immune-mediated granulomatous disorders and for metal antigen behavior.
Similar content being viewed by others
References
Infante P, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004;363:415–416.
Maier LA, Gunn C, Newman LS. Beryllium Disease. In: Rom WN and Markowitz SB editors. Environmental and Occupational Medicine, 4th ed, Philadelphia: Woltersw Kluwer/Lippincott Williams and Wilkins; 2007. pp. 1019–1038.
Sterner JH, Eisenbud M. Epidemiology of beryllium intoxication. Arch Industr Hyg Occup Med. 1951;4:123–151.
Curtis GH. Cutaneous hypersensitivity due to beryllium: a study of thirteen cases. AMA Arch Dermatol Syph. 1951;64: 470–482.
Hanifin JM, Epstein WL, Cline MJ. In vitro studies of granulomatous hypersensitivity to beryllium. J Invest Dermatol. 1970;55:284–288.
Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol. 1991;88:54–60.
Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: relevant issues in beryllium health surveillance. Am J Ind Med. 2004;46:453–462.
Fontenot AP, Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol. 2005;26:543–549.
Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med. 1997;156:109–115.
Sawyer RT, Doherty DA, Schumacher BA, Newman LS. Beryllium-stimulatedin vitro migration of peripheral blood lymphocytes. Toxicology. 1999;138:155–163.
Bost TW, Riches DW, Schumacher B, Carré PC, Khan TZ, Martinez JA, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and IL-6 but not IL-1β. Am J Respir Cell Mol Biol. 1994;10:506–513.
Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989;320:1103–1109.
Saltini C, Kirby M, Trapnell BC,Tamura N, Crystal RG. Biased accumulation of T lymphocytes with “memory”-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med. 1990;171:1123–1140.
Tinkle SS, Kittle LA, Schumacher BA, Newman LS. Beryllium induces IL-2 and IFN-gamma in berylliosis J Immunol. 1997;158:518–526.
Tinkle SS, Kittle LA, Newman LS. Partial IL-10 inhibition of cell-mediated immune response in chronic beryllium disease. J Immunol. 1999;163:2747–2753.
Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL. Target organ localization of CD4+T cells in patients with chronic beryllium disease. J Clin Invest. 2002;110:1473–1482.
Fontenot A, Kotzin B, Comment CE, Newman LS. Expansions of T cell subsets expressing particular T cell receptor variable regions in chronic beryllium disease Am J Respir Cell Mol Biol. 1998;18:581–589.
Fontenot AP, Falta MT, Freed BM, Newman LS, Kotzin BL. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999;163:1019–1026.
Fontenot AP, Palmer BE Sullivan AK, Joslin FG, Wilson CC, Maier LA, et al. Frequency of beryllium-specific, central memory CD4+T cells in blood determines proliferative response. J Clin Invest. 2005;115:2886–2893.
Fontenot AP Gharavi L, Bennett SR, Canavera SJ, Newman LS, Kotzin BL. CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+T cells. J Clin Invest. 2003;112:776–784.
Bobka CA, Stewart LA, Engelken GJ, Golitz LE, Newman LS. Comparison ofin vivo andin vitro measures of beryllium sensitization. J Occup Environ Med. 1997;39:540–547.
Fontenot AP, Maier LA, Canavera SJ, Hendry-Hofer TB, Boguniewicz M Barker EA, et al. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol. 2002;168:3627–3634.
Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, et al. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J. 2002;20:1174–1178.
Sawyer RT, Day BJ, Fadok VA, Chiarappa-Zucca M, Maier LA, Fontenot AP, et al. Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am J Respir Cell Mol Biol. 2004;31:470–477.
Richeldi L, Sorrentino R, Saltini C. HLA-DPBI glutamate 69:a genetic marker of beryllium disease. Science. 1993;262:242–244.
Newman LS. To Be2+ or not to Be2+: immunogenetics and occupational exposure. Science. 1993;262:197–198.
Fontenot AP Torres M, Marshall WH, Newman LS, Kotzin BL. Beryllium presentation to CD4+T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000;97:12717–12722.
Fontenot AP, Newman LS, Kotzin BL. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol. 2001;100:4–14.
Wang Z, White PS, Petrovic M, Tatum OL Newman LS, Maier LA, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and-DPA1 alleles. J Immunol. 1999;163:1647–1653.
Maier LA, Sawyer RT, Bauer RA, Kittle LA, Lympany P, McGrath D, et al. High beryllium-stimulated TNF-alpha is associated with the-308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med. 2001;164:1192–1199.
Wang Z, Farris GM, Newman LS, Shou Y, Maier LA, Smith HN, et al. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology. 2001;165:27–38.
Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, van den Berg-Loonen E, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J. 2001;18:677–684.
Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med. 2002;165:788–794.
Lombardi G, Germain C, Uren J, Fiorillo MT, du Bois RM, Jones-Williams W, et al. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol. 2001;166:3549–3555.
Weston A, Snyder J, McCanlies EC, Schuler CR, Andrew ME, Kreiss K, et al. Immunogenetic factors in beryllium sensitization and chronic beryllium disease. Mutat Res. 2005; 592:68–78.
McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: a HuGE review. Am J Epidemiol. 2003;157:388–398.
Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003;171:6910–6918.
Amicosante M, Fontenot AP. T cell recognition in chronic beryllium disease. Clin Immunol. 2006;121:134–143.
Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E, et al. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res. 2005;6:94.
Bill JR, Mack DG, Falta MT, Maier LA, Sullivan AK, Joslin FG, et al. Beryllium presentation to CD4+T cells is dependent on a single amino acid residue to the MHC class II betachain. J Immunol. 2005;175:7029–7037.
Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med. 1997;32:337–340.
Kittle LA, Sawyer RT, Fadok VA, Maier LA, Newman LS. Beryllium induces apoptosis in human lung macrophages. Sarcoidosis Vasc Diffuse Lung dis. 2002;19:101–113.
Sawyer RT, Parsons CE, Fontenot AP, Maier LA, Gillespie MM, Gottschall EB, et al. Beryllium-induced TNF-alpha production by CD4+T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol. 2004;31:122–130.
Sawyer RT, Dobis DR, Goldstein M, Velsor L, Maier LA, Fontenot AP, et al. Beryllium-stimulated reactive oxygen species and macrophage apoptosis. Free Radic Biol Med. 2005;38:928–937.
Sawyer RT, Fontenot AP Barnes TA, Parsons CE, Tooker BC, Maier LA, et al. Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease. Am J Respir Cell Mol Biol. 2007;36:191–200.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Newman, L.S. Immunotoxicology of beryllium lung disease. Environ Health Prev Med 12, 161–164 (2007). https://doi.org/10.1007/BF02897985
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02897985